Swedish Orphan Biovitrum AB International (SOBI) pharmaceuticals is conducting a phase 4, prospective, multi-center, open-label study to evaluate the safety, platelet count response, and subject reported satisfaction of treatment in adult subjects (18 years of age or older) with chronic ITP after switching to avatrombopag from eltrombopag or romiplostim. This study is for participants who have been undergoing treatment for primary ITP with eltrombopag or romiplostim for at least 90 days. Participants must have had a previous response (at any time) to either eltrombopag or romiplostim, defined as at least 2 platelet counts above 50,000uL. Patients will be treated with avatrombopag for up to 90 days.
Recruiting
USA
